Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Updates in kidney cancer at ESMO 2022

Joaquim Bellmunt • 12 Sep 2022
ESMO 2022
Genitourinary Cancer Kidney Cancer Antibodies Cabozantinib Nivolumab Pembrolizumab
COSMIC-313

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses updates from ESMO 2022 for renal cell carcinoma, including checkpoint inhibitors, adjuvant immunotherapy, and results from the COSMIC-313 trial (NCT03937219). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joaquim Bellmunt

1:44
The impact of mutational clonality on patient response to immunotherapies in UC
Joaquim Bellmunt • 22 Oct 2023
1:08
Key takeaways from the renal and prostate cancer sessions at ESMO 2023
Joaquim Bellmunt • 22 Oct 2023
1:52
Treatment options and their rollout for patients with metastatic urothelial carcinoma
Joaquim Bellmunt • 22 Oct 2023
3:38
Breakthroughs in urothelial cancer treatment at ESMO 2023
Joaquim Bellmunt • 22 Oct 2023

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals